Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

Entries for June 2014

20
- RNAi Therapeutic ARC-AAT Induces Dose Dependent Reductions in Mutant AAT Protein of Greater than 95 Percent in Preclinical Studies- Long Duration of Effect with AAT Remaining Reduced by More than 80% at 6 Weeks after a Single Dose- Company ...

[Read More...]

20
- Alnylam Remains On Track to File Investigational New Drug (IND) Application in Mid 2015 -Cambridge, Mass., and Miami, Fla., June 19, 2014 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (...

[Read More...]

10
The Alpha-1 Project, the venture philanthropy arm of the Alpha-1 Foundation, today announced it will fund a two-year postdoctoral fellowship position at the National Institutes of Health’s (NIH) National Center for Advancing Translational Sciences (N...

[Read More...]